Chronic myeloid leukaemia as a model of disease evolution in human cancer JV Melo, DJ Barnes Nature Reviews Cancer 7 (6), 441-453, 2007 | 746 | 2007 |
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia DJ Barnes, D Palaiologou, E Panousopoulou, B Schultheis, ASM Yong, ... Cancer research 65 (19), 8912-8919, 2005 | 260 | 2005 |
Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia DJ Barnes, JV Melo Cell cycle 5 (24), 2862-2866, 2006 | 147 | 2006 |
Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia DJ Barnes, JV Melo Acta haematologica 108 (4), 180-202, 2002 | 142 | 2002 |
Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells E Bonhoure, A Lauret, DJ Barnes, C Martin, B Malavaud, T Kohama, ... Leukemia 22 (5), 971-979, 2008 | 129 | 2008 |
Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia DJ Barnes, B Schultheis, S Adedeji, JV Melo Oncogene 24 (42), 6432-6440, 2005 | 104 | 2005 |
Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells C Chuah, DJ Barnes, M Kwok, A Corbin, MWN Deininger, BJ Druker, ... Leukemia 19 (11), 1896-1904, 2005 | 76 | 2005 |
Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate. AJ Tipping, S Baluch, DJ Barnes, DR Veach, BM Clarkson, WG Bornmann, ... Leukemia (08876924) 18 (8), 2004 | 67 | 2004 |
Igf2 pathway dependency of the Trp53 developmental and tumour phenotypes VL Haley, DJ Barnes, I Sandovici, M Constancia, CF Graham, F Pezzella, ... EMBO molecular medicine 4 (8), 705-718, 2012 | 41 | 2012 |
A germline mutation of CDKN2A and a novel RPLP1-C19MC fusion detected in a rare melanotic neuroectodermal tumor of infancy: a case report DJ Barnes, E Hookway, N Athanasou, T Kashima, U Oppermann, ... BMC cancer 16, 1-14, 2016 | 33 | 2016 |
Management of chronic myeloid leukemia: targets for molecular therapy DJ Barnes, JV Melo Seminars in hematology 40 (1), 34-49, 2003 | 31 | 2003 |
Igf2 ligand dependency of Pten+/− developmental and tumour phenotypes in the mouse DN Church, BR Phillips, DJ Stuckey, DJ Barnes, FM Buffa, S Manek, ... Oncogene 31 (31), 3635-3646, 2012 | 25 | 2012 |
Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines DJ Barnes, S De, P Van Hensbergen, E Moravcsik, JV Melo Leukemia 21 (3), 421-426, 2007 | 17 | 2007 |
A genetic model for central chondrosarcoma evolution correlates with patient outcome W Cross, I Lyskjær, T Lesluyes, S Hargreaves, AC Strobl, C Davies, ... Genome medicine 14 (1), 99, 2022 | 10 | 2022 |
Cut to the chase: on the need for genotype-specific soft tissue sarcoma trials A Gupta, D Church, D Barnes, AB Hassan Annals of oncology 20 (3), 399-400, 2009 | 9 | 2009 |
Chronic myeloid leukemia: biology of advanced phase JV Melo, JM Goldman, JV Melo, DJ Barnes Myeloproliferative Disorders, 37-58, 2007 | 8 | 2007 |
Switching off oncogenic signals in chronic myeloid leukaemia. J Melo, DJ Barnes The Hematology Journal: the Official Journal of the European Haematology …, 2004 | 8 | 2004 |
Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial) DJ Barnes, P Dutton, Ø Bruland, H Gelderblom, A Faleti, C Bühnemann, ... BMC cancer 22 (1), 629, 2022 | 7 | 2022 |
Epithelial-mesenchymal transition and nuclear β-catenin induced by conditional intestinal disruption of Cdh1 with Apc is E-cadherin EC1 domain dependent J Matheson, C Bühnemann, EJ Carter, D Barnes, HJ Hoppe, J Hughes, ... Oncotarget 7 (43), 69883, 2016 | 7 | 2016 |
BCR-ABL expression levels determine the rate of development of resistance to imatinib mesylate (Gleevec) B DJ Blood 102, 415, 2003 | 3 | 2003 |